{"filings":[{"id":973516,"accession_number":"0001628280-26-042237","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-06-10T20:27:32+00:00","items":["5.02"],"status":"ready","headline":"Vir Biotechnology appoints Timothy Coughlin as new director and Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 7 to 8 members; Timothy Coughlin appointed effective June 9, 2026.","Coughlin named Chair of the Audit Committee immediately upon appointment.","Will receive standard non-employee director cash and equity per company policy; no related-party transactions.","Received automatic stock option and RSU awards under the 2019 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":705756,"accession_number":"0001628280-26-038630","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-05-28T13:01:18+00:00","items":["5.02","5.07"],"status":"ready","headline":"Vir Biotechnology director Saira Ramasastry resigns; board shrinks to 7; annual meeting elects directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Saira Ramasastry steps down from board and audit committee effective May 26, 2026, due to business conflict; no disagreement with company.","Robert More appointed Audit Committee Chair; board size reduced from 8 to 7 upon Ramasastry's departure.","At May 26 annual meeting, Class I directors Robert More, Janet Napolitano, and Elliott Sigal elected; Napolitano received 67.2M for, 54.5M withheld.","Advisory vote on named executive officer compensation approved: 108.5M for, 11.9M against, 1.4M abstain.","Ratification of Ernst & Young as independent auditor for FY2026 approved: 137.0M for, 0.15M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94849,"accession_number":"0001628280-26-031273","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Bio Q1 net loss $125.7M; cash $809.3M; positive CHD data; VIR-5500 collaboration closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $125.7M ($0.85 per share) vs $121M ($0.88) in Q1 2025.","Cash, cash equivalents, and investments $809.3M at March 31, 2026; plus $315M Astellas upfront and equity in Q2.","Phase 2 SOLSTICE: 77% (24/31) HDV RNA undetectable at Week 72, rising to 88% (21/24) at Week 96.","Phase 3 ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2/3 in Q1 2027.","Completed $172.5M public offering; closed Astellas collaboration for VIR-5500; first patient dosed in Phase 1 expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":-29000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94848,"accession_number":"0001193125-26-151209","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Biotechnology CMO Mark Eisner to step down effective April 24, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Eisner, EVP and Chief Medical Officer, leaving role on April 24, 2026.","Company has initiated search for a successor; no replacement named yet.","Departure disclosed in Item 5.02 of the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107525,"accession_number":"0001193125-26-091447","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Bio appoints CEO Marianne De Backer to additional role of President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On March 4, 2026, Vir Bio's Board appointed CEO Marianne De Backer to the additional position of President.","No arrangements or understandings exist between Dr. De Backer and any person regarding her appointment as President.","No family relationship between Dr. De Backer and any Vir Bio director or executive officer.","Dr. De Backer has no direct or indirect interest in any transaction requiring Item 404(a) disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107524,"accession_number":"0001193125-26-084367","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vir Biotechnology closes $172.5M equity offering; underwriters exercise full over-allotment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 20,294,117 shares of common stock at $8.50 per share, raising ~$172.5M in gross proceeds.","Underwriters exercised in full the 30-day option to purchase an additional 2,647,058 shares on Feb 26, 2026.","Offering closed on February 27, 2026; net proceeds after discounts and expenses not disclosed.","Goldman Sachs, Leerink Partners, Evercore, and Barclays acted as representatives of the underwriters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107523,"accession_number":"0001193125-26-077416","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vir Biotechnology prices $150M public offering of 17.6M shares at $8.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 17,647,059 shares of common stock at $8.50 per share; over-allotment option for 2,647,058 shares.","Net proceeds estimated at $141.1M, or $162.3M if over-allotment fully exercised.","Underwriters include Goldman Sachs, Leerink Partners, Evercore, Barclays; closing expected Feb 27, 2026.","Proceeds for general corporate purposes; shares sold under existing S-3ASR shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107522,"accession_number":"0001628280-26-010740","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","2.02","3.02","8.01","9.01"],"status":"ready","headline":"Vir Biotechnology enters global strategic collaboration with Astellas for VIR-5500 prostate cancer T-cell engager","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vir Bio will receive $335 million in upfront and near-term payments, including $240M cash and $75M equity at 50% premium.","Eligible for up to $1.37 billion in development, regulatory and sales milestones plus tiered double-digit royalties on ex-U.S. net sales.","Global development costs shared 40% Vir Bio / 60% Astellas; U.S. profits/losses split 50/50 with Vir co-promotion option.","Phase 1 data for VIR-5500 shows dose-dependent anti-tumor activity; oral presentation at ASCO GU 2026 on February 26.","Cash and investments $781.6M as of Dec 31, 2025; net loss for full year 2025 was $438.0 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107521,"accession_number":"0001628280-26-001768","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vir Bio: 88% HDV RNA undetectable at Week 96 in combo arm; cash ~$781M, runway to Q4 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 SOLSTICE: 88% (21/24) of combo arm achieved undetectable HDV RNA at Week 96 vs 46% (11/24) monotherapy.","No grade 3+ treatment-related AEs in combo arm; generally mild/moderate and transient.","Cash, cash equivalents & investments ~$781M at Dec 31, 2025; runway extended into Q4 2027 via Norgine deal.","ECLIPSE 1 Phase 3 topline data expected Q4 2026; ECLIPSE 2/3 top-line in Q1 2027.","VIR-5500 Phase 1 data in prostate cancer to be presented at ASCO GU Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123878,"accession_number":"0001628280-25-057394","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Vir Bio licenses CHD combo to Norgine for EUR 55M upfront, up to EUR 495M milestones; cash runway extended to Q4 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive commercial license for tobevibart+elebsiran in Europe, Australia, New Zealand for chronic hepatitis delta.","Vir receives EUR 55M upfront, up to EUR 495M in milestones, plus tiered mid-teen to high-twenties % royalties.","Norgine to cover ~25% of go-forward external costs for ECLIPSE registrational program.","SOLSTICE Phase 2 data: 66% of CHD patients achieved HDV RNA target not detected at 48 weeks; well-tolerated.","Vir expects current cash, equivalents, and investments to extend into Q4 2027 under current operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123877,"accession_number":"0001628280-25-049561","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q3 net loss $163M ($1.17/sh); ECLIPSE enrollment ahead of schedule","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $163.1M ($1.17/sh) vs $213.7M ($1.56) in Q3 2024; revenues $0.2M.","Cash and investments $810.7M as of Sept 30, 2025; runway into mid-2027.","ECLIPSE 1 enrollment completed ~2 months early; topline data for all three HDV studies expected Q1 2027.","VIR-5500 first patient dosed in combo with ARPIs in 1L mCRPC; comprehensive data update planned Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":4486000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140547,"accession_number":"0001628280-25-038329","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotechnology Q2 net loss $111.0M; cash $892.1M; ECLIPSE program underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $111.0M ($0.80/share) vs $138.4M ($1.02) in Q2 2024; revenue $1.2M down from $3.1M.","Cash, investments $892.1M, down $127.7M sequentially; runway into mid-2027.","ECLIPSE registrational program for chronic hepatitis Delta fully underway; ECLIPSE 2 and 3 enrolling patients.","First patient dosed in Phase 1 of VIR-5525 (EGFR-targeting PRO-XTEN T-cell engager); three PRO-XTEN Phase 1 studies ongoing.","R&D expenses $97.5M (down from $105.1M) reflecting restructuring savings partially offset by clinical costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":4246000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140546,"accession_number":"0001628280-25-035847","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vir doses first patient in Phase 1 trial of EGFR-TCE VIR-5525; triggers $75M milestone payment to Sanofi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR, in solid tumors (NSCLC, CRC, HNSCC, cSCC).","Dosing triggers a $75M milestone payment to Sanofi under the 2024 license agreement, recognized as R&D expense in Q3 2025.","$75M milestone was held as restricted cash and excluded from the $1.02B cash reported as of March 31, 2025.","Dose escalation continues for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA) in heavily pretreated patients, showing early response signals.","VIR-5525 is Vir's third dual-masked TCE in clinical trials; preclinical candidates integrating PRO-XTEN and AI discovery are advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158249,"accession_number":"0001628280-25-028356","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vir Biotechnology stockholders elect directors, approve executive pay, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jeffrey S. Hatfield and Saira Ramasastry elected as Class III directors each with >93 million votes for.","Advisory vote on executive compensation approved: 100.5 million for, 4.3 million against.","Ernst & Young LLP ratified as independent auditor for FY 2025 (116.3 million for).","All three proposals passed; no material change in governance or operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158248,"accession_number":"0001628280-25-024067","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vir Biotech reports HBsAg loss in MARCH study but halts Phase 3 for chronic HBV without partner","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HBsAg loss 24 weeks post-treatment: 17% (3/18) and 21% (3/14) in low baseline HBsAg patients with tobevibart+elebsiran without/with PEG-IFNα.","No global development partner secured for chronic HBV; Phase 3 will not proceed.","Company to streamline final stages of MARCH Phase 2, focusing on hepatitis delta ECLIPSE Phase 3 and T-cell engager oncology programs.","Cash runway guidance into mid-2027 reaffirmed based on current operating plan.","Safety profile consistent; no new concerns; generally mild/moderate adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158247,"accession_number":"0001628280-25-023175","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q1 net loss $121M; launches Phase 3 hepatitis delta program; cash into mid-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $121.0M ($0.88 per share) vs $65.3M ($0.48) in Q1 2024; revenue $3.0M vs $56.4M.","Initiated Phase 3 ECLIPSE registrational program for chronic hepatitis delta; first patient enrolled March 2025.","Cash and investments ~$1.02B, down $75.6M in Q1; cash runway into mid-2027.","Alnylam opted out of profit-sharing for elebsiran in CHB/CHD; Vir seeking partner for CHB development.","Dose escalation ongoing for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA); Phase 1 for VIR-5525 (EGFR) planned Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":3032000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176626,"accession_number":"0001628280-25-008163","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotechnology reports Q4 and full year 2024 financial results and pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments of $1.10 billion as of Dec 31, 2024, providing cash runway into mid-2027.","Net loss for Q4 2024 was $104.6 million ($0.76 per share) vs $116.0 million ($0.86 per share) in Q4 2023.","Phase 3 ECLIPSE registrational program in chronic hepatitis delta on track for first patient in first half of 2025.","Initial Phase 1 data for VIR-5818 showed tumor shrinkage in 50% (10/20) of participants at doses ≥400 µg/kg.","Company plans to initiate Phase 1 study of VIR-5525, dual-masked EGFR-targeting T-cell engager, in first half 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":74205000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176625,"accession_number":"0001628280-25-003073","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Biotechnology CTO to depart Feb 26; Maninder Hora appointed as replacement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ann (Aine) M. Hanly, EVP and Chief Technology Officer, will leave Vir Biotechnology on February 26, 2025.","Maninder Hora, Ph.D. appointed as EVP and Chief Technical Operations Officer, effective February 27, 2025.","Dr. Hora will assume all responsibilities formerly held by Dr. Hanly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176624,"accession_number":"0001193125-25-003214","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vir Biotech reports encouraging Phase 1 data: 50% tumor shrinkage (VIR-5818), 58% PSA50 (VIR-5500)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VIR-5818 (HER2): 50% (10/20) tumor shrinkage at doses ≥400 µg/kg; cPR in 33% (2/6) HER2+ CRC.","VIR-5500 (PSMA mCRPC): PSA declines in 100% (12/12) and PSA50 response in 58% (7/12) at first dose ≥120 µg/kg.","Safety: No dose-limiting CRS; max grade 2 CRS; MTD not reached for either TCE; dosing up to 1000 µg/kg.","PRO-XTEN masking technology shows minimal systemic unmasking; half-life 6-10 days enabling Q3W dosing.","Phase 1 trials ongoing; dose escalation continues; company to hold investor call Jan 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193466,"accession_number":"0001628280-24-044563","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q3 net loss $213.7M; closes Sanofi TCE licensing deal, appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $213.7M ($1.56 per share) vs $163.4M ($1.22) in Q3 2023; revenue $2.4M, down from $2.6M.","Closed exclusive worldwide license with Sanofi for three dual-masked T-cell engagers; paid $103.7M upfront.","Workforce reduction of ~25% (140 employees) as part of restructuring; expects ~435 employees by year-end.","Jason O'Byrne appointed as CFO effective Oct 2, 2024; brings 20+ years finance experience.","R&D expenses surged to $195.2M (including $102.8M Sanofi upfront IPR&D); SG&A down to $25.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":61831000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209778,"accession_number":"0001628280-24-039948","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["2.01","5.02","7.01","9.01"],"status":"ready","headline":"Vir closes $100M Sanofi license deal for three T-cell engagers; appoints new CFO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed exclusive worldwide license with Sanofi for 3 clinical-stage masked TCEs (SAR446309, SAR446329, SAR446368) and PRO-XTEN platform for oncology/infectious disease.","Upfront payment $100M plus $75M escrowed milestone; up to $323M dev/reg milestones, $1.488B sales milestones, and low single to low double-digit tiered royalties.","Jason O'Byrne appointed EVP and CFO effective Oct 2, 2024; base salary $530K, target bonus 45%, sign-on $450K, equity awards of 150K options and 75K RSUs.","Clinical assets: SAR446309 (HER2) in Phase 1, SAR446329 (PSMA) in Phase 1, SAR446368 (EGFR) IND active, Phase 1 start expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209777,"accession_number":"0001628280-24-034143","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Vir Bio Q2 net loss narrows to $138M; initiates restructuring cutting 25% of workforce","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $138.4M ($1.02/sh) vs $194.8M ($1.45/sh) in Q2 2023; cash and investments $1.43B, down $78M in quarter.","Strategic restructuring reduces workforce by ~140 employees (25%); phases out flu, COVID-19, and T-cell viral vector programs.","Expects $11–13M in restructuring charges, ~$50M annual workforce cost savings from 2025, and ~$50M program savings through 2025.","Lowers full-year 2024 GAAP operating expense guidance to $580–610M, excluding Sanofi transaction impact.","Signed exclusive worldwide license with Sanofi for clinical-stage T-cell engagers; CMO Mark Eisner appointed June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":59451000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209776,"accession_number":"0001193125-24-191500","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vir Biotechnology licenses three clinical-stage masked T-cell engagers from Sanofi for $100M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $100M plus $75M escrowed milestone for SAR446368 (AMX-525) first-in-human dosing by 2026.","Eligible for up to $323M in development/regulatory milestones and up to $1.488B in commercial sales milestones.","License covers SAR446309, SAR446329, and SAR446368 (AMX-525) masked T-cell engagers and protease-cleavable masking platform.","Exclusive worldwide license for oncology and infectious disease, excluding ophthalmology; low single-digit to low double-digit tiered royalties.","Closing contingent on expiration or termination of applicable HSR waiting period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227963,"accession_number":"0001193125-24-168554","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vir Biotech gets FDA IND clearance & Fast Track for hepatitis delta combo therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND and granted Fast Track for tobevibart + elebsiran for chronic hepatitis delta.","Phase 2 SOLSTICE 24-week data expected Q4 2024; preliminary data showed high virologic response.","Company plans ECLIPSE trial to support potential registration, comparing combo to standard of care.","CEO Marianne De Backer says IND clearance underscores potential to transform treatment landscape.","Hepatitis delta affects at least 12 million people globally; considered most severe viral hepatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227962,"accession_number":"0001193125-24-154636","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vir reports high virologic response in Phase 2 SOLSTICE hepatitis delta trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["De novo tobevibart+elebsiran combination: 64% (7/11) combined endpoint at week 24.","Tobevibart monotherapy: 55% (6/11) combined endpoint at week 24.","No serious adverse events, no ALT flares; majority of AEs Grade 1-2 and transient.","Company to report additional 24-week data for all ~60 participants in Q4 2024.","Data to be presented at EASL Congress on June 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227961,"accession_number":"0001193125-24-149139","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vir Biotechnology shareholders elect Class II directors, approve advisory compensation, ratify EY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors De Backer, Bischofberger, Farid, Nelsen elected with votes for/withheld: 105.6M/1.1M, 80.0M/26.7M, 106.4M/0.3M, 67.9M/38.8M; broker non-votes 12.3M.","Advisory vote on executive compensation approved: 83.9M for, 22.6M against, 0.2M abstain; broker non-votes 12.3M.","Ratification of Ernst & Young as auditor: 118.1M for, 679,046 against, 168,971 abstain; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227960,"accession_number":"0001628280-24-020009","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotechnology Q1 net loss narrows to $65.3M; CFO stepping down; pipeline catalysts ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $65.3M ($0.48 loss per share) vs $140.9M ($1.06) in Q1 2023; revenue $56.4M down 10.5% YoY.","Cash, equivalents & investments $1.51B, down $118M in Q1; FY2024 R&D+SG&A guidance reaffirmed $650-680M.","CFO Sung Lee stepping down effective May 3; successor search initiated.","SOLSTICE hepatitis delta late-breaker abstract accepted at EASL June; 24-week data expected Q4 2024.","MARCH hepatitis B data and HIV VIR-1388 immunogenicity data expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":56376000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227959,"accession_number":"0001193125-24-100072","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"CFO Sung Lee resigns effective May 3; board nominates two new independent directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Sung Lee resigns effective May 3, 2024, to pursue other opportunity; no disagreement with company.","Board nominates Norbert Bischofberger and Ramy Farid as independent director candidates for May 29 annual meeting.","Founders Phillip Sharp and Robert Perez will not stand for reelection at the annual meeting.","Bischofberger brings 40 years biotech experience (former Gilead R&D head); Farid is CEO of Schrödinger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246723,"accession_number":"0001628280-24-006346","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Vir Biotech Q4/FY2023 net loss $116M/$615M; GSK flu pact ended; cash $1.63B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $116.0M ($0.86 loss per share); FY2023 net loss $615.1M ($4.59 loss per share).","Q4 revenue $16.8M (down 66% YoY); FY revenue $86.2M (down 95% YoY) on lower sotrovimab sales.","Cash, cash equivalents and investments $1.63B as of Dec 31, 2023, down $108M in Q4.","GSK influenza collaboration terminated; Vir retains sole rights to VIR-2482, VIR-2981 and pays low single-digit royalties.","CMO Phil Pang steps down March 31, 2024; SOLSTICE hepatitis delta trial enrollment ahead of schedule with initial data expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":86180000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246722,"accession_number":"0001193125-24-040034","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Biotechnology CMO Phil Pang to leave at end of March 2024; successor search started","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Executive VP and Chief Medical Officer Phil Pang, M.D., Ph.D. departing at end of March 2024, citing family reasons.","Company has initiated a search for a new Chief Medical Officer.","No interim CMO named; transition expected by end of March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264168,"accession_number":"0001193125-23-294328","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Vir Biotechnology to cut 12% of workforce, close R&D sites; charges $30-40M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~75 positions (12%) and closure of St. Louis and Portland R&D facilities in 2024.","Estimated pre-tax charges of $30-40M, primarily facility-related; $3-4M cash expenditures. Annual savings at least $40M.","Company to focus on chronic hepatitis delta/B programs and expand monoclonal antibody platform into autoimmune and oncology.","Research to continue at San Francisco and Bellinzona sites.","Cash, equivalents, and investments of $1.7B as of Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264167,"accession_number":"0001193125-23-270462","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Vir Biotechnology enters $300M at-the-market equity facility with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement allows Vir to sell up to $300M of common stock through TD Cowen as agent.","Commission of up to 3.0% on gross proceeds; Cowen may use customary at-the-market methods.","Prior 2020 sales agreement with TD Cowen terminated; no shares were sold under the prior facility.","Shares sold under existing S-3 shelf registration statement filed November 3, 2023.","Company not obligated to sell any shares; facility provides optional capital-raising flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264166,"accession_number":"0001628280-23-036397","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotechnology Q3 net loss $163.4M; revenue down 99% YoY on sotrovimab sales decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $163.4M ($1.22/share) vs net income of $175.3M ($1.32/share) in Q3 2022.","Total revenue $2.6M, down 99.3% from $374.6M a year ago due to lower sotrovimab sales.","Cash, equivalents and investments $1.7B; $67M paid to GSK for excess sotrovimab supply.","Secured ~$50M in new BARDA funding to advance next-gen COVID-19 mAb VIR-7229 through Phase 1.","Appointed Jennifer Towne, Ph.D., as EVP and Chief Scientific Officer, effective Nov 6, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":69393000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264165,"accession_number":"0001193125-23-249556","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vir Biotechnology receives $50M from BARDA for next-gen COVID-19 mAb and pandemic preparedness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BARDA awards $40M via Project NextGen for VIR-7229 Phase 1 trial, expected completion H2 2025.","Additional $10M for discovery of mAbs against a second pandemic-potential pathogen.","Vir also receives ~$11M to wind down PENINSULA trial of influenza A mAb VIR-2482.","Existing BARDA Agreement allows up to $1B total investment; $55M already provided for VIR-2482.","Funds support alternative mAb delivery technologies for COVID-19 and broader pandemic response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281422,"accession_number":"0001193125-23-237943","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Biotechnology COO Johanna Friedl-Naderer to depart Sept 29; role not replaced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["EVP and COO Johanna Friedl-Naderer will leave Vir Biotechnology on September 29, 2023.","The COO role will not be filled; responsibilities assigned to other management team members.","No successor has been named for the departing officer.","Departure announced September 20, 2023, effective shortly thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281421,"accession_number":"0001628280-23-027227","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q2 net loss $194.8M; hep B/delta data on track for Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $194.8M ($1.45/sh) vs $76.5M loss YoY; revenues $3.8M (incl $16.5M grant).","Cash $1.9B at June 30; $273.6M paid to GSK for excess sotrovimab supply.","Discontinued innate immunity small molecule platform to focus on antibody platform.","Phase 2 PENINSULA flu trial (VIR-2482) missed primary and secondary endpoints.","Phase 2 hep B/delta data (VIR-2218/VIR-3434) expected Q4 2023; HIV vaccine VIR-1388 Phase 1 dosing expected Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":66754000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281420,"accession_number":"0001193125-23-190147","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Vir Bio Phase 2 flu prevention trial misses endpoints; cash ~$1.9B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 PENINSULA trial of VIR-2482 did not meet primary or secondary efficacy endpoints for preventing symptomatic influenza A.","Highest dose (1,200 mg) showed non-statistically significant 16% reduction in protocol-defined influenza A illness vs placebo.","Secondary endpoint (CDC-defined ILI) showed 57% reduction, but not statistically significant (95% CI -2.51 to 82.15).","VIR-2482 was generally well tolerated; no safety signals identified; ~3,000 participants enrolled.","Cash, cash equivalents and investments were approximately $1.9 billion as of June 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300233,"accession_number":"0000950170-23-023627","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vir Biotechnology annual meeting: directors elected, say-on-pay and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Robert More, Janet Napolitano, Vicki Sato, and Elliott Sigal as Class I directors; each received over 98M votes for.","Advisory vote on executive compensation approved: 106.0M for, 4.4M against, 97K abstentions, 8.3M broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2023 approved: 118.7M for, 41.7K against, 109.8K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300232,"accession_number":"0000950170-23-017880","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q1 revenue $63M (down 95% YoY); net loss $140.9M; new CEO Marianne De Backer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 total revenues $63M vs $1.2B in Q1 2022 (-94.9%); net loss of $140.9M ($1.06/sh) vs net income of $518.6M.","Cash, equivalents, and investments $2.3B at March 31; anticipates ~$272M payment to GSK in Q2 2023 for excess sotrovimab.","Marianne De Backer joined as CEO in April 2023; Sung Lee appointed EVP & CFO in March 2023.","Pipeline: Phase 2 data readouts for influenza (mid-2023), hepatitis B (2023), hepatitis D (H2 2023); $10M Gates Foundation grant for HIV vaccine trial.","R&D expenses rose to $157.6M (up 75% YoY) driven by VIR-2482 influenza antibody program."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":62957000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320272,"accession_number":"0001193125-23-067978","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Vir Biotechnology discloses $220M exposure to Silicon Valley Bank after FDIC seizure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDIC took control of Silicon Valley Bank (SVB) on March 10, 2023.","Vir holds approximately $220 million in operating accounts at SVB as of March 10.","Total cash, cash equivalents and investments were $2.4 billion as of December 31, 2022.","Company is monitoring the situation but has not disclosed any impact on operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320271,"accession_number":"0001193125-23-064485","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Vir Biotechnology amends bylaws with enhanced stockholder nomination requirements and procedural updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eliminated requirement to make stockholder list available at meeting; added adjournment for technical failure.","Enhanced disclosure requirements for stockholder nominations and proposals, including Rule 14a-19 compliance.","Non-compliance with Rule 14a-19 may result in disregarding nominees and votes.","Added emergency bylaw provision for director and officer authority during crises.","Other technical, conforming, and clarifying changes made to reflect Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320270,"accession_number":"0000950170-23-004092","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q4 net loss $101.6M; CEO Scangos retiring, CFO Horn resigning","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $49.4M vs $812.7M YoY; net loss $0.76/share vs net income $4.01/share.","Full year 2022 revenue $1.6B, net income $515.8M ($3.89/share); cash & investments ~$2.4B.","CEO George Scangos retiring April 3, 2023; succeeded by Marianne De Backer (Bayer exec).","CFO Howard Horn resigning; replaced by Sung Lee, 20-year biotech veteran.","Key pipeline catalysts: HBV data H1 2023, influenza PENINSULA data mid-2023, HDV data H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":1615797000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320269,"accession_number":"0001193125-23-044204","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NICE recommends Vir's sotrovimab for COVID-19 in UK; no meaningful 2023 sales expected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NICE final draft guidance recommends sotrovimab for high-risk adults where Paxlovid is contraindicated or unsuitable.","Recommendation based on cost-effectiveness evaluation of sotrovimab.","No meaningful additional UK sales of sotrovimab anticipated in 2023 due to existing inventory.","Sotrovimab (Xevudy) authorized in over 40 countries; not authorized in the US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320268,"accession_number":"0001193125-23-040755","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Biotechnology names Sung Lee CFO, replacing Howard Horn effective March 27","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sung Lee appointed EVP and CFO effective March 27, 2023; Howard Horn steps down as CFO but remains EVP through April 28.","Base salary $525K, target bonus 45%, sign-on cash bonus $500K payable on 1-year anniversary, relocation expenses up to ~$460K.","Equity awards: option for 133K shares and RSUs for 66.5K shares, each vesting over 4 years.","Lee previously served as CFO at MorphoSys AG and Sangamo; prior roles at Gilead Sciences.","Severance provides 12 months pay/benefits + full equity acceleration within 12 months post-change-in-control; 9 months pay outside CIC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320267,"accession_number":"0001193125-23-035908","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vir Bio amends GSK deal: regains full rights to vaccine program, narrows antibody program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendments remove CoV Vaccine Program from collaboration; Vir retains rights to progress independently.","CoV Antibody Program narrowed to only sotrovimab and VIR-7832; all other antibodies revert to Vir.","Vir pays tiered royalties in low single digits on vaccine sales, low-to-mid single digits on terminated antibodies.","Amendments effective March 31, 2022 (vaccine wind-down) and February 8, 2023 (antibody scope reduction).","GSK retains 50:50 profit share on sotrovimab and VIR-7832 under original DCA terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320266,"accession_number":"0001193125-23-014834","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Biotechnology appoints Marianne De Backer as CEO effective April 3, 2023; George Scangos retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Scangos notified Board of retirement as CEO and President, effective April 3, 2023.","Marianne De Backer (ex-Bayer EVP) appointed CEO and Class II director effective same date.","De Backer receives $900K base salary, 80% target bonus, $5M sign-on bonus in two installments.","Equity awards valued up to $45M (1,152,904 stock options + 576,452 RSUs) vesting over 4 years.","Relocation package: $21K/month for up to 18 months plus final moving expenses to San Francisco."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338410,"accession_number":"0000950170-22-021846","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q3 revenue $374.6M; BARDA contract up to $1B; Phase 2 data in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 revenue $374.6M (vs $103.6M YoY); net income $175.3M ($1.32 basic EPS) vs $110.4M ($0.85) in Q3 2021.","BARDA awards contract for pandemic preparedness: initial ~$55M, potential up to $1B.","GSK opted-in to collaborate on RSV antibodies; profit-sharing from GSK $291.2M in Q3.","Phase 2 trials for HBV, HDV (SOLSTICE), influenza A (PENINSULA); initial data expected in 2023.","Strong balance sheet: ~$2.7B cash, investments, and profit-share payments."],"consensus_eps_estimate":null,"consensus_eps_actual":4.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":1566387000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338409,"accession_number":"0001193125-22-257259","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vir Biotechnology awarded up to $1B BARDA contract for influenza and pandemic preparedness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BARDA to invest ~$55M initially for VIR-2482 (influenza prophylactic mAb) development through Jan 2026.","Phase 2 trial of VIR-2482 expected to start H2 2022; initial data anticipated mid-2023.","Potential total investment up to $1B if BARDA exercises up to 12 options for additional candidates.","Contract supports development of up to 10 emerging infectious disease or medical countermeasure candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355772,"accession_number":"0000950170-22-016046","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Q2 net loss $76.5M; revenue negative on $397.4M non-cash charge; >$2.6B cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $76.5M ($0.58 per share) vs net income of $61.8M ($0.48) in Q2 2021.","Total revenue negative ($40.6M) due to $397.4M non-cash charge for excess sotrovimab supply and manufacturing capacity.","Collaboration revenue from GSK was ($54.9M); $342.5M profit-share expected in Q3 2022.","Cash, equivalents, investments and profit-share payments exceed $2.6B, expected to fund operations for up to five years.","HERBERT 'SKIP' VIRGIN, CSO, stepping down Aug 30; CMO Phil Pang to lead R&D on interim basis."],"consensus_eps_estimate":null,"consensus_eps_actual":3.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1191830000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355771,"accession_number":"0001193125-22-211859","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vir Biotechnology delays Q2 2022 earnings release to Aug 9, 2022 to finalize results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will issue Q2 2022 earnings release on August 9, 2022 after market close.","Delay allows additional time to finalize financial results for the quarter ended June 30, 2022.","Quarterly Report on Form 10-Q remains scheduled for filing on or before its due date of August 9, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-04T23:59:59+00:00|355771"}